Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn’s disease in the UK (COMMODUS)
The OBD provides a safe, easy to use and convenient way to self-administer risankizumab at home using one injection with improved satisfaction and confidence vs self-administration of four PFS in hospital.
Authors
- Adil Jaulim (ORCID: https://orcid.org/0000-0002-0552-6795)
- Fraser Cummings (ORCID: https://orcid.org/0000-0002-9659-3247)
- Mary Doona (ORCID: https://orcid.org/0000-0001-9533-3745)
- Ana Ibarra (ORCID: https://orcid.org/0000-0002-6855-1859)
- Sherill Tripoli
- Shahida Din (ORCID: https://orcid.org/0000-0003-2855-3400)
- Mark Samaan (ORCID: https://orcid.org/0000-0002-4057-9200)
- Mark A. Sephton (ORCID: https://orcid.org/0000-0002-2190-5402)
- James O. Lindsay (ORCID: https://orcid.org/0000-0003-3353-9590)
- Ally Speight (ORCID: https://orcid.org/0000-0003-3184-9181)
- Rachel Horsfall
- David Young (ORCID: https://orcid.org/0000-0003-0102-5739)
- Anna Stanton
Institutions
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Barts Health NHS Trust (GB)
- Western General Hospital (GB)
- Royal Victoria Infirmary (GB)
- Royal London Hospital (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Edinburgh Cancer Research (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- AbbVie (United States) (US)
- AbbVie (United Kingdom) (GB)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1080/03007995.2025.2506808
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00